2-叔丁基-E-乙烯基硼酸 | 86595-37-1

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 2-叔丁基-E-乙烯基硼酸
• 中文别名: 2-叔丁基-反式-乙烯基硼酸；3,3-二甲基-1-丁烯硼酸
• 英文名称: trans-2-tert-butylvinylboronic acid
• 英文别名: (E)-(3,3-dimethylbut-1-en-1-yl)boronic acid；[(E)-3,3-dimethylbut-1-enyl]boronic acid；(E)-3,3-dimethyl-1-butenylboronic acid；3,3-Dimethyl-1-butenylboronic acid
• CAS: 86595-37-1
• 化学式: C₆H₁₃BO₂
• 分子量: 127.979
• InChiKey: CTIWKIMYFQSVBZ-SNAWJCMRSA-N

物化性质

• 熔点：
  78-80
• 沸点：
  212.4±23.0 °C(Predicted)
• 密度：
  0.926±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-t-Butyl-E-vinylboronic acid
Product Name:
Synonyms: 3,3-Dimethyl-1-butenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-t-Butyl-E-vinylboronic acid
Ingredient name:
CAS number: 86595-37-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H13BO2
Molecular weight: 128.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-叔丁基-E-乙烯基硼酸 在 sodium hydroxide 、 碘 作用下， 以 乙醚 为溶剂， 反应 0.5h， 以85%的产率得到(E)-1-iodo-3,3-dimethyl-1-butene
  参考文献：
  名称：

  Vinylic organoboranes. 14. A stereospecific synthesis of (E)-1-halo-1-alkenes from 1-alkynes

  摘要：

  DOI：

  10.1021/jo00287a019
• 作为产物：
  描述：

  3,3-二甲基-1-丁炔 在 二溴硼烷甲硫醚络合物 、 sodium hydroxide 、 ammonium hydroxide 作用下， 以 二氯甲烷 为溶剂， 以63%的产率得到2-叔丁基-E-乙烯基硼酸
  参考文献：
  名称：

  环丙烷衍生物的动力学酶解

  摘要：

  系统研究了各种环丙烷衍生物的动力学酶解。该研究集中于合成有用的环丙基甲醇（例如18a / j或19a / j）以及一些鲜有研究的环丙醇（例如24/25或27）。对映体富集化合物的对映选择性催化或非对映选择性合成与酶促方法的结合最终导致最方便的途径制备对映体纯的起始原料。再次证明了这一点，特别是对于环丙醇18a / j和19a / j的合成。成功进行研究的关键是严格建立一种分析工具，用于分析反应混合物的对映体组成。

  DOI：

  10.1002/adsc.200303137

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties
  作者：Ganesha Rai、Daniel J. Urban、Bryan T. Mott、Xin Hu、Shyh-Ming Yang、Gloria A. Benavides、Michelle S. Johnson、Giuseppe L. Squadrito、Kyle R. Brimacombe、Tobie D. Lee、Dorian M. Cheff、Hu Zhu、Mark J. Henderson、Katherine Pohida、Gary A. Sulikowski、David M. Dranow、Md Kabir、Pranav Shah、Elias Padilha、Dingyin Tao、Yuhong Fang、Plamen P. Christov、Kwangho Kim、Somnath Jana、Pavan Muttil、Tamara Anderson、Nitesh K. Kunda、Helen J. Hathaway、Donna F. Kusewitt、Nobu Oshima、Murali Cherukuri、Douglas R. Davies、Jeffrey P. Norenberg、Larry A. Sklar、William J. Moore、Chi V. Dang、Gordon M. Stott、Leonard Neckers、Andrew J. Flint、Victor M. Darley-Usmar、Anton Simeonov、Alex G. Waterson、Ajit Jadhav、Matthew D. Hall、David J. Maloney

  DOI：10.1021/acs.jmedchem.0c00916

  日期：2020.10.8

  of compounds, using structure-based design concepts, coupled with optimization of cellular potency, in vitro drug–target residence times, and in vivo PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibition in vivo. The lead compounds, named NCATS-SM1440 (43) and NCATS-SM1441 (52), possess desirable attributes for further studying the effect of in vivo LDH inhibition.

  乳酸脱氢酶（LDH）催化丙酮酸向乳酸的转化，同时还原的烟酰胺腺嘌呤二核苷酸的氧化是糖酵解途径的最后一步。糖酵解在癌细胞的代谢可塑性中起重要作用，长期以来一直被认为是潜在的治疗靶点。因此，LDH的有效的选择性抑制剂代表了一种有吸引力的治疗方法。然而，迄今为止，药理剂未能实现体内显着的靶标结合，可能是因为蛋白质以非常高的浓度存在于细胞中。我们在此报告了一项领先的优化运动，该研究使用基于结构的设计概念，重点研究了吡唑基系列化合物，并在体外优化了细胞效能药物-靶标的停留时间和体内PK特性，以鉴定可证明LDH在体内具有抑制作用的一流抑制剂。名为NCATS-SM1440（43）和NCATS-SM1441（52）的先导化合物具有进一步研究体内LDH抑制作用所需的属性。
• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE
  申请人：VERTEX PHARMA

  公开号：WO2021030556A1

  公开（公告）日：2021-02-18

  This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

  这份披露提供了囊性纤维化跨膜传导调节蛋白（CFTR）的调节剂，包含至少一种这样的调节剂的药物组合物，使用这种调节剂和药物组合物治疗囊性纤维化的方法，以及制造这种调节剂的过程。
• A Four-Component Reaction for the Synthesis of Dioxadiazaborocines
  作者：Thomas Flagstad、Mette T. Petersen、Thomas E. Nielsen

  DOI：10.1002/anie.201502989

  日期：2015.7.13

  A four‐component reaction for the synthesis of heterocyclic boronates is reported. Readily available hydrazides, α‐hydroxy aldehydes, and two orthogonally reactive boronic acids are combined in a single step to give structurally distinct bicyclic boronates, termed dioxadiazaborocines (DODA borocines). In this remarkable process, one boronic acid reacts as a carbon nucleophile and the other as a boron

  据报道，四价反应可合成杂环硼酸盐。现成的酰肼，α-羟基醛和两种正交反应的硼酸可在一个步骤中结合在一起，得到结构上不同的双环硼酸酯，称为二氧杂氮杂硼硼烷（DODA硼硼烷）。在这一非同寻常的过程中，一种硼酸以碳亲核体的形式发生反应，另一种以硼亲电子体的形式发生反应，从而以高收率提供具有多个立体中心的对映体和非对映体纯杂环硼酸酯。
• Enantioselective Palladium-Catalyzed Alkenylation of Trisubstituted Alkenols To Form Allylic Quaternary Centers
  作者：Harshkumar H. Patel、Matthew S. Sigman

  DOI：10.1021/jacs.6b09649

  日期：2016.11.2

  In this report, we describe the generation of remote allylic quaternary stereocenters β, γ, and δ relative to a carbonyl in high enantioselectivity. We utilize a redox-relay Heck reaction between alkenyl triflates and acyclic trisubstituted alkenols of varying chain-lengths. A wide array of terminal (E)-alkenyl triflates are suitable for this process. The utility of this functionalization is validated

  在本报告中，我们描述了相对于羰基以高对映选择性生成远程烯丙基四元立体中心 β、γ 和 δ。我们利用链烯基三氟甲磺酸酯和不同链长的无环三取代烯醇之间的氧化还原中继 Heck 反应。多种末端 (E)-烯基三氟甲磺酸酯适用于该过程。这种功能化的效用通过产品的转化得到进一步验证，通过简单的有机过程获得远程功能化的手性叔酸、胺和醇产品。